NASDAQ:TXG • US88025U1097
The current stock price of TXG is 19.1 USD. In the past month the price decreased by -15.11%. In the past year, price increased by 78.67%.
ChartMill assigns a technical rating of 8 / 10 to TXG. When comparing the yearly performance of all stocks, TXG is one of the better performing stocks in the market, outperforming 89.09% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to TXG. TXG has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 71.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.43% | ||
| ROE | -9.72% | ||
| Debt/Equity | 0 |
21 analysts have analysed TXG and the average price target is 18.43 USD. This implies a price decrease of -3.49% is expected in the next year compared to the current price of 19.1.
For the next year, analysts expect an EPS growth of -122.99% and a revenue growth -3.48% for TXG
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.77 | 194.032B | ||
| DHR | DANAHER CORP | 24.63 | 149.099B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 142.41 | 47.173B | ||
| A | AGILENT TECHNOLOGIES INC | 20.55 | 35.129B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.84 | 28.325B | ||
| IQV | IQVIA HOLDINGS INC | 12.6 | 27.528B | ||
| WAT | WATERS CORP | 22.55 | 19.513B | ||
| ILMN | ILLUMINA INC | 23.74 | 18.418B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.26 | 17.569B | ||
| MEDP | MEDPACE HOLDINGS INC | 26.31 | 12.535B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
10X GENOMICS INC-CLASS A
6230 Stoneridge Mall Road
Pleasanton CALIFORNIA 94588 US
CEO: Serge Saxonov
Employees: 1306
Phone: 13026587581
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
The current stock price of TXG is 19.1 USD. The price increased by 1.11% in the last trading session.
TXG does not pay a dividend.
TXG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
TXG stock is listed on the Nasdaq exchange.
21 analysts have analysed TXG and the average price target is 18.43 USD. This implies a price decrease of -3.49% is expected in the next year compared to the current price of 19.1.
10X GENOMICS INC-CLASS A (TXG) currently has 1306 employees.